Equities By Region UK Pharmaceuticals & Health

AstraZeneca share price: Company completes drugs divestment to Covis

Share this article!

AstraZeneca (LON:AZN) has completed the divestment of the rights of several respiratory treatments to Switzerland-based Covis Pharma, the blue-chip group has said. The news comes after earlier this week, the Anglo-Swedish drugmaker wrapped up the disposal of some rights to Nexium and Vimovo, to Grünenthal.

AstraZeneca’s share price has been trading in the red in London in today’s session, having given up 1.27 percent to 5,975.00p as of 14:49 GMT. The shares, however, are outperforming the broader market selloff which has seen the benchmark FTSE 100 index tumble 2.73 percent to 6,732.72 points so far today, as the arrest of a Huawei executive in Canada reignited fears over the US-China trade relations.

AstraZeneca completes another disposal

AstraZeneca announced in a statement today that it had completed an agreement with Covis Pharma to sell its rights to the medicines Alvesco, used for the treatment of persistent asthma, and Omnaris and Zetonna, which are used to treat  nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines. The transaction does not include the transfer of any of the FTSE 100 drugmaker’s employees or facilities to the Swiss company.

The transaction, first announced last month, is part of the blue-chip pharmco’s ongoing strategy to divest non-core assets as it looks to focus on its pipeline of new treatments to propel growth going forward.

Blue-chip group lands $350 million from deal

AstraZeneca said that it had received a payment of $350 million from Covis for the deal, and will report it in the Other Operating Income & Expense section of its financial statement for the last quarter of the year. The blue-chip pharmco said that the agreement does not affect its financial guidance for the current year.

As of 15:06 GMT, Thursday, 06 December, AstraZeneca plc share price is 5,990.00p.

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.